文献速递肝病

肝性脑病与MELD-Na预测自身免疫性肝炎相关失代偿期肝硬化的治疗获益

Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-04-08

这项回顾性国际多中心研究纳入232例组织学确诊的自身免疫性肝炎相关失代偿期肝硬化患者,采用竞争风险分析(肝移植为竞争事件)评估死亡风险。治疗者死亡风险较低(SHR 0.438;95%CI 0.196-0.981;P=0.045),无3/4级肝性脑病且MELD-Na≤28者更可能获益,治疗4周后MELD-Na下降≥11对死亡/肝移植有100%阴性预测值。

要点

  • 治疗者死亡风险较低(SHR 0.438;95%CI 0.196-0.981;P=0.045)。
  • 无3/4级肝性脑病且MELD-Na≤28者更可能从治疗中获益。
  • 治疗4周后MELD-Na下降≥11对死亡/肝移植有100%阴性预测值。

核心结论

  • 免疫抑制对活动性自身免疫性肝炎相关失代偿期肝硬化患者有益。
  • 诊断时肝性脑病和MELD-Na以及治疗4周时MELD-Na下降是结局的最重要决定因素,可指导治疗决策。

研究设计与样本

  • 回顾性、国际、多中心研究,纳入232例诊断时组织学确诊的自身免疫性肝炎相关失代偿期肝硬化患者。
  • 采用竞争风险分析确定死亡风险的亚风险比(SHR),以肝移植为竞争事件。
  • 采用决策树分析制定治疗算法。

主要发现

  • 诊断时89%的患者有腹水,41%有显性肝性脑病(OHE)。
  • 接受治疗的患者(n=214;92%)转氨酶、胆红素和改良肝活动指数较高。
  • 治疗者死亡SHR较低(0.438;95%CI 0.196-0.981;P=0.045)。
  • 诊断时无3/4级OHE且MELD-Na≤28的患者更可能从治疗中获益;在这些患者中,治疗4周后MELD-Na下降≥11对死亡/肝移植有100%阴性预测值。
  • 随访期间49%的治疗者出现再代偿;20%的患者不得不停止治疗,其中65%发生在最初4周内,仅4%因感染并发症停药;诊断时OHE≥2级和MELD-Na预测需要停止治疗。

关键数值与推荐

  • 治疗者死亡SHR为0.438(95%CI 0.196-0.981;P=0.045)。
  • 诊断时无3/4级OHE且MELD-Na≤28的患者更可能从治疗中获益。
  • 治疗4周后MELD-Na下降≥11对死亡/肝移植有100%阴性预测值。

临床怎么用

  • 诊断时OHE和MELD-Na以及治疗4周时MELD-Na下降可指导自身免疫性肝炎相关失代偿期肝硬化的治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Management of patients with autoimmune hepatitis (AIH)-related decompensated cirrhosis is challenging because of the risk of treatment-related complications and lack of clinical recommendations. We investigated the predictive factors for treatment benefit in AIH-related decompensated cirrhosis at diagnosis and developed an algorithm to guide treatment decisions in clinical practice. METHODS: This retrospective, international, multicenter study included 232 patients with histologically confirmed AIH-related decompensated cirrhosis at diagnosis. The sub-hazard ratio (SHR) of mortality was determined by competing risk analysis, considering liver transplantation (LT) as competing event. A decision tree analysis was used to develop a treatment algorithm. RESULTS: At diagnosis, 89% of patients had ascites, and 41% had overt hepatic encephalopathy (OHE). Treated patients (n = 214; 92%) had higher aminotransferases, bilirubin, and modified hepatic activity index. The SHR of mortality was lower in treated patients (0.438; 95% confidence interval [CI], 0.196-0.981; P = .045). Patients without OHE grade 3/4 and Model for End-Stage Liver Disease-Sodium (MELD-Na) ≤28 at diagnosis were more likely to benefit from treatment. In these patients, a decline in MELD-Na ≥11 after 4 weeks of treatment had a 100% negative predictive value for death/LT. Forty-nine percent of treated patients recompensated during follow-up. Twenty percent of patients had to discontinue treatment, 65% during the first 4 weeks, and only 4% due to infectious complications. OHE ≥grade 2 and MELD-Na at diagnosis predicted the need for treatment discontinuation. CONCLUSIONS: Immunosuppression is beneficial in patients with AIH-related decompensated cirrhosis and active disease. OHE and MELD-Na at diagnosis, along with a decline in MELD-Na at 4 weeks of treatment, are the most important determinants of outcome and can guide treatment decisions.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Arvaniti P, Rodríguez-Tajes S, Padilla M, et al. Hepatic Encephalopathy and MELD-Na Predict Treatment Benefit in Autoimmune Hepatitis-related Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2025. PMID: 40210079. doi:10.1016/j.cgh.2025.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。